Role of Oxytocin in Myocardial Infarction
Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction
Eligibility Criteria
Inclusion Criteria:
- age > 18 years
- current diagnosis of ST elevation myocardial infarction
- no previous episodes of acute coronary syndrome
- agreed to enter research
Exclusion Criteria:
- age < 18 years
- congestive heart failure (acute or chronic)
- cardiomyopathy
- life threatening arrhythmia at presentation
- previous LV dysfunction
- hypotension (systolic < 100mmHg, diastolic<50mmHg, 15% less than patients normal values)
- tachycardia - pulse > 100bpm
- bradycardia - pulse < 55 ppm
- killip 3 or 4 at presentation
- current use of nitrates
- pregnancy
- females - history of pathological GU bleeding
- inability to give consent
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
conventional treatment and oxytocin
conventional treatment only
26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.